The National Cancer Institute’s Office of Cancer Clinical Proteomics Research is the host of two primary programs: the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Antibody Characterization Program. Governance for CPTAC comes internally from the CPTAC Steering Committee, while additional advice and insight for both CPTAC and the Antibody Characterization Program is provided from members of the extramural research community not affiliated with CPTAC.
The programs in the Office of Cancer Clinical Proteomics Research (OCCPR) are led and coordinated by a project team comprised of health scientists with expertise in basic and applied research, regulatory science, clinical assay development, bioinformatics, therapeutics, and clinical chemistry at the National Cancer Institute (NCI). Click here to view brief biographies of the team members.
CPTAC is governed by an internal Steering Committee that provides strategic coordination for the activities of the Proteome Characterization Centers (PCCs). The Steering Committee is composed of the Principal Investigators from each of the PCCs, with each PCC receiving an equal voice in the decision making process. To view the members of the CPTAC Steering Committee, click here.
CPTAC receives advice from its External Scientific Committee (ESC), whose membership includes patient advocates, senior scientists and clinicians with relevant expertise in cancer, genomics and proteomics. The members of the ESC are not principal investigators for or funded by CPTAC. To view the members of the CPTAC ESC, click here.
The Antibody Scientific Committee provides scientific insight and advice to the National Cancer Institute's Antibody Characterization Program. Specifically the members of this committee evaluate request from the external scientific community for production and characterization of antibodies by the program. To view the members of the Antibody Selection committee, click here.